文献速递临床免疫质量管理与危急值

血浆GFAP免疫测定验证及年龄相关参考值建立

Validation of a plasma GFAP immunoassay and establishment of age-related reference values: bridging analytical performance and routine implementation.
PubMed 文献 · Clin Chem Lab Med · 2025-08-25

本研究分两阶段验证MSD S-Plex® GFAP血浆免疫测定并建立年龄分层参考区间。第一阶段按CLSI等指南评估重复性、中间精密度、测量范围、干扰与样本稳定性;第二阶段基于579名17–91岁表观健康个体,用右侧非参数百分位法推导参考区间。结果显示分析性能良好,重复性与中间精密度CV均低于12%,并建立三个年龄组的上限参考值。

要点

  • 重复性与中间精密度CV均低于12%,分析性能良好
  • 年龄分层上限参考值:18–<50岁38 pg/mL,≥50–<70岁73 pg/mL,≥70岁156 pg/mL
  • 50岁后女性GFAP绝对水平高于男性,年龄与GFAP强正相关

核心结论

  • MSD S-Plex® GFAP血浆免疫测定分析性能稳健,并建立了年龄相关参考值,支持其常规临床使用。

研究设计与样本

  • 研究分两阶段:第一阶段按CLSI及已发表方案指南评估重复性、中间精密度、测量范围、干扰和样本稳定性。
  • 第二阶段从579名17–91岁表观健康个体中,用右侧非参数百分位法推导参考区间,并计算三个预设年龄组的上限参考值及连续年龄依赖百分位模型。

主要发现

  • 重复性和中间精密度变异系数低于12%。
  • 计入1:2稀释比例后,验证测量范围为0.425–1760 ng/L,所有校准残差在±15%以内。
  • GFAP浓度不受溶血影响(p=0.85),在4 °C及冷冻条件下稳定长达7天。
  • 年龄与血浆GFAP水平呈强正相关(Spearman's r=0.832,p<0.0001)。
  • 50岁后观察到性别差异,女性GFAP绝对水平高于男性。

关键数值与推荐

  • 血浆GFAP年龄分层上限参考值:38 pg/mL(18–<50岁)、73 pg/mL(≥50–<70岁)、156 pg/mL(≥70岁)。
  • 验证测量范围0.425–1760 ng/L(计入1:2稀释比例),校准残差在±15%以内。
  • 溶血对GFAP浓度无影响(p=0.85),样本在4 °C及冷冻条件下稳定长达7天。

临床怎么用

  • 可依据年龄分层上限参考值解读血浆GFAP,用于神经退行性疾病、神经炎症和急性脑损伤等中枢神经系统病理的辅助诊断与监测。
  • 解读时应考虑年龄与性别差异,50岁后女性GFAP绝对水平较高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Glial fibrillary acidic protein (GFAP) is a well-established biomarker of astrocytic activation associated with neurodegenerative diseases, neuroinflammatory disorders, and traumatic brain injury. With increasing interest in blood-based biomarkers, the need for analytically validated assays and reliable reference intervals is critical for routine clinical implementation. This study aimed to analytically validate the MSD S-Plex® GFAP immunoassay for plasma and to establish age-stratified reference intervals in an apparently healthy population. METHODS: This study was conducted in two phases. First, key analytical validation parameters - including repeatability, intermediate precision, measurement range, interferences, and sample stability - were evaluated following Clinical and Laboratory Standards Institute (CLSI) and published protocol guidelines. Second, reference intervals were derived from 579 apparently healthy individuals aged 17-91 years using a right-sided non-parametric percentile method. Age-specific upper reference limits were calculated for three predefined age groups, and a continuous age-dependent centile model was applied. RESULTS: MSD S-Plex® GFAP assay demonstrated strong analytical performance, with coefficients of variation for repeatability and intermediate precision below 12 %. After accounting for the 1:2 dilution ratio, the validated measurement range was 0.425-1760 ng/L, with all calibration residuals remaining within ±15 %. GFAP concentrations were unaffected by hemolysis (p=0.85) and remained stable for up to 7 days at 4 °C and under frozen storage conditions. Age-stratified upper reference limits for plasma GFAP were established as 38 pg/mL (18-<50 years), 73 pg/mL (≥50-<70 years), and 156 pg/mL (≥70 years). Additionally, sex-related differences were observed after age 50, with females showing higher absolute GFAP levels than males. A strong positive correlation between age and plasma GFAP levels was observed (Spearman's r=0.832, p<0.0001). CONCLUSIONS: This study demonstrates the robust analytical performance of the MSD S-Plex® GFAP assay and establishes age-related reference values for plasma GFAP. These findings support its suitability for routine clinical use and enhance its applicability in the diagnosis and monitoring of central nervous system (CNS) pathologies, such as neurodegenerative diseases, neuroinflammatory disorders, and acute brain injuries, within biomarker-supported clinical algorithms.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Arslan B, Andreasson U, Rembeza E, et al. Validation of a plasma GFAP immunoassay and establishment of age-related reference values: bridging analytical performance and routine implementation. Clin Chem Lab Med. 2025. PMID: 40842193. doi:10.1515/cclm-2025-0870

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。